BioAtla, Inc.

BCAB

Exchange: OTC
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001826892

SEC filings (opens in a new tab)

No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding BioAtla, Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026 All holders in Q1 2026

13F holders of BCAB: Q1 2026 compared with Q2 2026
Measure	Q1 2026	Q2 2026	Change
Holders	36	21	−15
SharesConverted for a 1-for-50 split	313.4K	295.5K	−17.8K (−5.7%)
Value	$2.52M	$1.22M	−$1.29M (−51.5%)

New holders (4)

Institutions that held BioAtla, Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to BCAB in Q2 2026
Institution	Shares	Value	% of portfolio
Lido Advisors, LLC	16,656	$69.0K	0.00%
HRT Financial LP	13,276	$54.0K	0.00%
Forum Finance Group S.A.	400	$1.00K	0.00%
Barclays PLC	101	$418	0.00%

Sold out (19)

Institutions that held BioAtla, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.

Institutions that sold out of BCAB in Q2 2026
Institution	Shares, Q1 2026	Value, Q1 2026
Renaissance Technologies LLC	510,514	$82.2K
Citadel Advisors LLC	435,675	$70.1K
Marshall Wace, LLP	277,630	$44.4K
ADAR1 Capital Management, LLC	228,107	$36.7K
State Street Corp	151,377	$24.4K
Northern Trust Corp	103,494	$16.7K
Simplex Trading, LLC	73,901	$11.9K
XTX Topco Ltd	56,614	$9.12K
MAI Capital Management	51,504	$8.29K
Kestra Advisory Services, LLC	44,250	$7.12K
Susquehanna International Group, LLP	39,056	$6.29K
StoneX Group Inc.	29,466	$4.74K
Commonwealth Equity Services, LLC	25,300	$4.07K
Jane Street Group, LLC	23,142	$3.73K
Magnus Financial Group LLC	20,000	$3.22K
Vanguard Global Advisers, LLC	16,635	$2.68K
Mariner, LLC	16,000	$2.58K
Torrey Growth & Income Advisors	15,687	$2.36K
Advisor Group Holdings, Inc.	500	$80